Bristol-Myers Squibb and Simcere Enter Partnership to Co-Develop and Co-Commercialize Orencia(R) SC (abatacept) in China
PRINCETON, N.J. & NANJING, China--(Healthcare Sales & Marketing Network)--Bristol-Myers Squibb Company (BMY) and Simcere Pharmaceutical Group (SCR), a leading pharmaceutical company in China, today announced that the companies have expanded their strategic... BiopharmaceuticalsBristol-Myers Squibb, Simcere Pharmaceutical, Orencia, abatacept (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - June 14, 2013 Category: Pharmaceuticals Source Type: news
In Rheumatoid Arthritis, Abatacept As Effective As Adalimumab, With Fewer Injection Site Reactions
Data from AMPLE presented at EULAR 2013, the Annual Congress of the European League Against Rheumatism, demonstrate comparable efficacy and similar safety profiles between subcutaneous abatacept (ABA) and adalimumab (ADA). AMPLE, the first two-year head-to-head biologics trial, was comprised of 646 biologic-naïve patients with active rheumatoid arthritis (RA) equally randomised to either ABA or ADA, with a stable dose of methotrexate (MTX). 79.2% (252 of 318) ABA patients and 74.7% (245 of 328) ADA patients completed the trial... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - June 14, 2013 Category: Consumer Health News Tags: Arthritis / Rheumatology Source Type: news
ORENCIA® shows comparable efficacy to Humira®
Bristol-Myers Squibb Company (NYSE: BMY) has announced the results of year two data from AMPLE (Abatacept Versus Adalimumab Comparison in Biologic-Naïve rheumatoid arthritis (RA) Subjects With Background Methotrexate), a first-of-its-kind trial of 646 patients comparing the safety and efficacy of the subcutaneous (SC) formulation of abatacept versus adalimumab, each on a background of MTX, in biologic naïve patients with moderate to severe RA. (Source: Pharmacy Europe)
Source: Pharmacy Europe - June 12, 2013 Category: Drugs & Pharmacology Source Type: news
Abatacept as effective as adalimumab in rheumatoid arthritis
(European League Against Rheumatism) Data from AMPLE presented at EULAR 2013, the Annual Congress of the European League Against Rheumatism, demonstrate comparable efficacy and similar safety profiles between subcutaneous abatacept and adalimumab. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 12, 2013 Category: Global & Universal Source Type: news
Low Antibody Response Seen With RA Drug (CME/CE)
(MedPage Today) -- Few rheumatoid arthritis patients treated with abatacept (Orencia) developed immunogenic responses that could interfere with efficacy and safety of the biologic agent, an international study found. (Source: MedPage Today Geriatrics)
Source: MedPage Today Geriatrics - May 1, 2013 Category: Geriatrics Source Type: news
SMC recommends abatacept
The Scottish Medicines Consortium (SMC) has announced today that abatacept (Orencia®) has been accepted for use within NHS Scotland, in combination with methotrexate (MTX), as a first-line biologic agent for adults with rheumatoid arthritis (RA), after failure with two conventional DMARDs. (Source: Pharmacy Europe)
Source: Pharmacy Europe - April 8, 2013 Category: Drugs & Pharmacology Source Type: news
Abatacept Use After Failure of Multiple Biologics in RAAbatacept Use After Failure of Multiple Biologics in RA
How safe and effective is abatacept in treating RA patients who have failed multiple therapies? Journal of Clinical Rheumatology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 20, 2013 Category: Consumer Health News Tags: Rheumatology Journal Article Source Type: news
Orencia® (abatacept) 125mg solution for injection - New Formulation
Source: eMC (electronic Medicines Compendium)
Area: Other Library Updates > SPC Changes
Bristol-Myers Squibb has been granted marketing authorisation for a new formulation given by subcutaneous injection.
Orencia® (abatacept) in combination with methotrexate is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who responded inadequately to previous therapy with one or more disease-modifying anti-rheumatic drugs including methotrexate or a tumour necrosis factor-alpha inhibitor.
Please see link to SPC for full prescribing information. (...
Source: NeLM - SPC Changes - February 11, 2013 Category: Drugs & Pharmacology Source Type: news
Abatacept, Adalimumab Equal for RA in Head-to-Head Trial Abatacept, Adalimumab Equal for RA in Head-to-Head Trial
Subcutaneous abatacept and subcutaneous adalimumab were comparably effective when added to background methotrexate for patients with rheumatoid arthritis who had no previous exposure to biologicals. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 12, 2013 Category: Consumer Health News Tags: Rheumatology News Source Type: news
